Find More Contacts for Sonendo
Protected Content
CTO
Executive Engineering
1 email found 1 phone number found
View contacts for Sonendo to access new leads and connect with decision-makers.
View All Contacts

Details

  • Contact Email info@sonendo.com
  • Phone Number (949) 766-3636

Sonendo developing innovative technologies to transform dentistry by Saving Teeth Through Sound Science®. The GentleWave® System shows significant improvements in clinical efficacy and practice efficiency when compared to standard root canal treatment.1,2, 3 Sonendo is the parent company of TDO® Software, the developer of the most widely used

endodontic practice management software in the world, designed to simplify practice workflow. TDO software seamlessly integrates practice management, imaging, social media, referral reporting, CBCT imaging, and offers built-in communication with the GentleWave System.

Lists Featuring This Company

California Public Companies With More Than 10 Employees
1,145 Number of Organizations • $573.4B Total Funding Amount • 6,947 Number of Investors
West Coast Companies With Fewer Than 1000 Employees (Top 10K)
9,851 Number of Organizations • $809.7B Total Funding Amount • 85,125 Number of Investors
Western US Companies With More Than 10 Employees (Top 10K)
9,944 Number of Organizations • $1.7T Total Funding Amount • 86,926 Number of Investors
Western US Companies (Top 10K)
9,944 Number of Organizations • $1.6T Total Funding Amount • 89,264 Number of Investors

Frequently Asked Questions

Where is Sonendo's headquarters? Sonendo is located in Laguna Hills, California, United States.Who invested in Sonendo? Sonendo has 21 investors including First Light Asset Management and Blue Water Life Science Advisors.How much funding has Sonendo raised to date? Sonendo has raised .When was the last funding round for Sonendo? Sonendo closed its last funding round on Sep 23, 2022 from a Post-IPO Equity round.Who are Sonendo's competitors? Alternatives and possible competitors to Sonendo may include Eikon TherapeuticsProlocor, and Carisma Therapeutics.